A Phase 1 interventional study of IDP-126 Gel and Control Gel in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-10-21.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 28th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 1, and was the 29th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
By country, each count listing its studies:
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 247 across the 35 interventional studies, 200 across the 1 observational. Of the 31 that completed or were terminated, 19 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be an open-label study designed to assess the safety and plasma PK of topically applied IDP-126 Gel compared to Control Gel.
To evaluate the safety and plasma pharmacokinetics (PK) of clindamycin and adapalene in IDP-126 Gel compared with that from Control Gel in subjects with moderate to severe acne vulgaris (acne) during once daily topical application of IDP-126 Gel for 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Component A
Drug: IDP-126 Gel
Gel
Drug: Control Gel
Component A
gel
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).
During the study, subjects will be assessed for the occurrence of new and ongoing AEs. Descriptions of AEs will include the dates of onset and resolution, maximum severity, seriousness, action taken regarding study drug, corrective treatment, outcome, and investigator's assessment of causality. Worsening of disease will not be considered an AE unless it results in discontinuation of the subject from the study or requires medical intervention prohibited by the protocol.
Time frame: All AEs will be followed from onset of the adverse event through the end of Study Day 28 visit
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2018 to primary completion in Jun 2019, 10 months.
Of 44 industry-sponsored phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 7. This study's 10 months is above that.
Counting every sponsor, half of 51 studies reached it within 5 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IDP-126
Bausch Health Americas, Inc. →